“Attention-deficit/hyperactivity disorder (ADHD)is a common neurobehavioral condition affecting children and adolescents impairing academic success, self-esteem, and social interactions. Since there is no cure for ADHD, the public relies on researchers to provide an honest and objective evaluation of treatment options to help those with ADHD manage the disorder. The public’s expectation was thwarted when a study was published in the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP)in August 2021,titled Double-Blind Placebo-Controlled Randomized Clinical Trial of Neurofeedback for Attention-Deficit/Hyperactivity Disorder with 13-Month Follow-Up[Hereafter, abbreviated as “study” or “Arnold et al.”]. The study intended to evaluate neurofeedback as a treatment for ADHD over a 13-month period. The principal investigator and lead author was L. Eugene Arnold, MD, along with a team of coauthors collectively known as the Neurofeedback Collaborative Group. The study may be accessed in the JAACAP, 2021-07-01, Volume 60, Issue 7, pages 841–855. This study was supported by a $2 million grant from the National Institute of Mental Health (NIMH) #R01-MH100144, by Ohio State University College of Medicine Endowment, and by a Clinical and Translational Science award 8UL18TR000090-05 from the National Center for Translational Sciences.”
